Human complement bactericidal responses to a group a meningococcal conjugate vaccine in africans and comparison to responses measured by 2 other group a immunoassays

Gregory A. Price, Aimee M. Hollander, Brian D. Plikaytis, Brian T. Mocca, George Carlone, Helen Findlow, Raymond Borrow, Samba O. Sow, Aldiouma Diallo, Olubukola T. Idoko, Godwin C. Enwere, Cheryl Elie, Marie Pierre Preziosi, Prasad S. Kulkarni, Margaret C. Bash

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Background. PsA-TT (MenAfriVac) is a conjugated polysaccharide vaccine developed to eliminate group A meningococcal disease in Africa. Vaccination of African study participants with 1 dose of PsA-TT led to the production of anti-A polysaccharide antibodies and increased serum bactericidal activity measured using rabbit complement (rSBA). Bactericidal responses measured with human complement (hSBA) are presented here. Methods. Sera collected before and at 28 days and 1 year after vaccination with either PsA-TT or quadrivalent polysaccharide vaccine (PsACWY) from a random, age-distributed 360-subject subset of the Meningitis Vaccine Project study of PsA-TT in Africans aged 2-29 years were tested for hSBA. Geometric mean titer, fold-rise, and threshold analyses were compared between vaccine groups and age groups. hSBA, rSBA, and immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) results were compared and assay correlation and agreement determined. Results. hSBA responses to PsA-TT were substantially higher than those to PsACWY at 28 days and 1 year following immunization, similar to previously reported rSBA and IgG Results. The hSBA and IgG ELISA results identified differences between age groups that were not evident by rSBA. The rSBA data indicated sustained high titers 1 year after immunization, whereas hSBA GMTs at 1 year approached 4 in young children. Conclusions. The high level of protection following PsA-TT immunization campaigns is consistent with the strong hSBA immune responses observed here. Future implementation decisions will likely depend on immunologic data and their long-term correlation with disease and carriage prevention. Expanded immunologic and epidemiologic surveillance may improve the interpretation of differences between these immunoassays.

Original languageEnglish
Pages (from-to)S554-S562
JournalClinical Infectious Diseases
Volume61
DOIs
Publication statusPublished - 15 Nov 2015

Keywords

  • MenAfriVac
  • Neisseria meningitidis
  • assay development
  • bactericidal activity
  • clinical trials

Fingerprint

Dive into the research topics of 'Human complement bactericidal responses to a group a meningococcal conjugate vaccine in africans and comparison to responses measured by 2 other group a immunoassays'. Together they form a unique fingerprint.

Cite this